ALCOX.PA Stock - Nicox S.A.
Unlock GoAI Insights for ALCOX.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.86M | $6.90M | $3.27M | $7.23M | $12.91M |
| Gross Profit | $6.75M | $-11,503,043 | $-14,721,000 | $-10,677,000 | $179,000 |
| Gross Margin | 85.9% | -166.6% | -450.0% | -147.6% | 1.4% |
| Operating Income | $-9,853,646 | $-17,055,978 | $-34,061,000 | $-46,010,000 | $-6,760,000 |
| Net Income | $-22,389,639 | $-20,881,000 | $-31,285,000 | $-43,761,000 | $-18,098,000 |
| Net Margin | -284.9% | -302.5% | -956.4% | -605.0% | -140.2% |
| EPS | $-0.35 | $-0.42 | $-0.62 | $-1.17 | $-0.54 |
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.
Visit WebsiteEarnings History & Surprises
ALCOX.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q3 2025 | Jul 16, 2025 | — | — | — | — |
Q2 2025 | Apr 30, 2025 | $-0.08 | — | — | — |
Q1 2025 | Jan 23, 2025 | — | — | — | — |
Q4 2024 | Oct 17, 2024 | — | — | — | — |
Q3 2024 | Jul 18, 2024 | $-0.08 | — | — | — |
Q2 2024 | Apr 22, 2024 | $-0.07 | — | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.42 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.62 | — | — |
Latest News
Frequently Asked Questions about ALCOX.PA
What is ALCOX.PA's current stock price?
What is the analyst price target for ALCOX.PA?
What sector is Nicox S.A. in?
What is ALCOX.PA's market cap?
Does ALCOX.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALCOX.PA for comparison